Cencora Inc (COR)

Currency in USD
266.70
+4.83(+1.84%)
Real-time Data·
COR is included in our AI-picked strategies. See how they work
Fair Value
Day's Range
261.33268.87
52 wk Range
244.82377.54
Key Statistics
Prev. Close
261.87
Open
263.54
Day's Range
261.33-268.87
52 wk Range
244.82-377.54
Volume
939.66K
Average Volume (3m)
1.64M
1-Year Change
-8.8679%
Book Value / Share
17.47
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
COR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
357.00
Upside
+33.86%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Cencora Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Analyst Ratings

12 Buy
2 Hold
0 Sell
Ratings:
14 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 357.00
(+33.86% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
TD Cowen
Buy400.00+49.77%-MaintainMay 11, 2026
Wells Fargo
Buy331.00+23.93%429.00MaintainMay 11, 2026
Morgan Stanley
Buy342.00+28.05%400.00MaintainMay 08, 2026
UBS
Buy412.00+54.26%410.00MaintainMay 07, 2026
Baird
Buy339.00+26.93%420.00MaintainMay 07, 2026

Cencora Inc SWOT Analysis


Specialty Powerhouse
Cencora's dominance in specialty pharmaceuticals drives growth, with strategic acquisitions like RCA expanding its footprint in high-value markets
Financial Resilience
Strong Q3 results and raised FY24 guidance showcase Cencora's robust performance, with 24 years of consistent dividends and 20 years of growth
Market Dynamics
Explore how Cencora navigates industry trends, including the impact of GLP-1 drugs and post-pandemic market normalization on its growth trajectory
Future Prospects
Analyst targets range from $263 to $290, reflecting optimism about Cencora's potential in the evolving healthcare distribution landscape
Read full SWOT analysis

Cencora Inc Earnings Call Summary for Q2/2026

  • Cencora Q2 FY2026 EPS of $4.75 missed estimates of $4.83; revenue of $78.4B fell short of $81B forecast, triggering 16.7% stock decline.
  • Revenue grew 4% YoY to $78.4B; gross profit rose 16% to $3.4B, aided by OneOncology acquisition despite biosimilar conversion headwinds.
  • Company raised full-year EPS guidance to $17.65-$17.90 from $17.45-$17.75, but cut revenue growth outlook to 4%-6% from prior range.
  • Slower-than-expected GLP-1 market growth and accelerated biosimilar conversions pressured results; stock fell to near 52-week low of $271.
  • Management cited strategic acquisitions and digital transformation investments as key strengths despite Q2 challenges and market headwinds.
Last Updated: 05/06/2026, 10:16 PM
Read Full Transcript

Earnings

Latest Release
May 06, 2026
EPS / Forecast
4.75 / 4.83
Revenue / Forecast
78.4B / 80.97B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 13.05%
Dividend Yield
0.93%
Industry Median 1.71%
Annualized payout
2.40
Paid quarterly
5-Years Growth
+5.98%
Growth Streak

COR Income Statement

Compare COR to Peers and Sector

Metrics to compare
COR
Peers
Sector
Relationship
P/E Ratio
20.4x20.8x−0.5x
PEG Ratio
0.380.750.00
Price/Book
15.3x4.6x2.6x
Price / LTM Sales
0.2x1.7x3.2x
Upside (Analyst Target)
34.6%32.3%55.3%
Fair Value Upside
Unlock2.3%9.7%Unlock

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company’s U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
109.20M56.13%28.60B
Other Institutional Investors
89.85M43.87%23.53B
Public Companies & Retail Investors
0.000.00%0.00
Total
199.05M100.00%52.13B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
The Vanguard Group, Inc.12.14%23,617,1176,184,614
BlackRock, Inc.10.42%20,282,8875,311,480

People Also Watch

55.97
FISV
-1.23%
243.75
ADSK
+0.11%
201.79
CAH
+1.01%
408.43
AMAT
-1.24%
59.18
CNC
+1.63%

FAQ

What Is the Cencora Inc (COR) Stock Price Today?

The Cencora Inc stock price today is 266.70 USD.

What Stock Exchange Does Cencora Inc Trade On?

Cencora Inc is listed and trades on the New York Stock Exchange.

What Is the Stock Symbol for Cencora Inc?

The stock symbol for Cencora Inc is "COR."

Does Cencora Inc Pay Dividends? What’s The Current Dividend Yield?

The Cencora Inc dividend yield is 0.92%.

What Is the Cencora Inc Market Cap?

As of today, Cencora Inc market cap is 51.96B USD.

What Is Cencora Inc's Earnings Per Share (TTM)?

The Cencora Inc EPS (TTM) is 13.05.

When Is the Next Cencora Inc Earnings Date?

Cencora Inc will release its next earnings report on Aug 05, 2026.

From a Technical Analysis Perspective, Is COR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Cencora Inc Stock Split?

Cencora Inc has split 3 times.

How Many Employees Does Cencora Inc Have?

Cencora Inc has 49000 employees.

What is the current trading status of Cencora Inc (COR)?

As of May 19, 2026, Cencora Inc (COR) is trading at a price of 266.70 USD, with a previous close of 261.87 USD. The stock has fluctuated within a day range of 261.33 USD to 268.87 USD, while its 52-week range spans from 244.82 USD to 377.54 USD.

What Is Cencora Inc (COR) Price Target According to Analysts?

The average 12-month price target for Cencora Inc is 357.00 USD, with a high estimate of 425 USD and a low estimate of 280 USD. 12 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +33.86% Upside potential.

What Is the COR Premarket Price?

COR's last pre-market stock price is 258.85 USD. The pre-market share volume is 90.00, and the stock has decreased by -3.02, or -1.15%.

What Is the COR After Hours Price?

COR's last after hours stock price is 263.00 USD, the stock has decreased by 1.13, or 0.43%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.